%0 Journal Article %T GLP-1RA药物司美格鲁肽的临床应用研究进展
Research Progress on the Clinical Application of GLP-1RA Drug Semaglutide %A 陈曦 %A 王熙函 %A 薛姝蓉 %A 聂志凯 %A 王洪彬 %J Advances in Clinical Medicine %P 853-861 %@ 2161-8720 %D 2024 %I Hans Publishing %R 10.12677/acm.2024.1482293 %X 司美格鲁肽作为新兴的胰高血糖素样肽-1受体激动剂(GLP-1RA),是该药物类别中最近批准的药物,也是目前唯一可用于皮下注射和口服制剂的GLP-1RA,主要用于2型糖尿病的治疗。其药物特性可在血糖控制、胰岛素抵抗改善、体重管理、肝脏疾病上体现出显著的效果。在心脑血管疾病上也可体现出一定的治疗效果,成为当前医疗行业的热点。然而有利必有弊,司美格鲁肽的过度依赖也会伴随一些疾病的风险,如延缓胃排空导致的胃肠疾病、胰腺炎、胆道疾病等风险。本文通过分析司美格鲁肽的安全性和危险性,介绍该药物在降血糖、减重、治疗心血管疾病等多方面的进展,为临床应用提供参考。
Semaglutide, an emerging glucagon-like peptide-1 receptor agonist (GLP-1RA), is the most recently approved drug in this drug class and the only GLP-1RA currently available for subcutaneous and oral formulations, primarily for the treatment of type 2 diabetes. Its medicinal properties have been shown to be effective in blood sugar control, improvement of insulin resistance, weight management, and liver disease. It can also reflect a certain therapeutic effect in cardiovascular and cerebrovascular diseases, which has become a hot spot in the current medical industry. However, there are pros and cons, and the over-reliance on semaglutide will also be accompanied by the risk of some diseases, such as gastrointestinal diseases caused by delayed gastric emptying, pancreatitis, biliary tract diseases, etc. This article analyzes the safety and danger of semaglutide, and introduces the progress of semaglutide in blood glucose reduction, weight loss, and treatment of cardiovascular diseases, so as to provide reference for clinical application. %K 司美格鲁肽, %K 2型糖尿病, %K 减肥
Semaglutide %K Type 2 Diabetes Mellitus %K Lose Weight %U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=94491